Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/29/2025 10:29 PDT] AARD SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/23/2025 13:20 PDT] AARD SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/20/2025 11:45 PDT] AARD SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/20/2025 07:37 PDT] AARD Expected to Trade Up After Bullish Patterns Develop
• [05/15/2025 06:58 PDT] AARD Expected to Trade Down Short Term
• [05/12/2025 10:48 PDT] AARD SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/09/2025 10:48 PDT] Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD), Up By 100% ($10.56) After BUYINS.NET SqueezeTrigger Report Released on Wednesday, May 7th 2025 at a Price of $10.56.
• [05/07/2025 08:16 PDT] AARD SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/02/2025 14:36 PDT] Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD), Up By 100% ($11.31) From $11.31 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/02/2025 12:23 PDT] Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD), Up By 100% ($10.57) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, April 29th 2025 at a Price of $10.57.
• [04/30/2025 07:53 PDT] AARD Expected to Trade Up After Bullish Patterns Develop
• [04/29/2025 10:29 PDT] AARD SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/04/2025 07:37 PDT] AARD Expected to Trade Up After Bullish Patterns Develop